Chapter 12. Target-Directed Drug Discovery
- Sotiris Missailidis
Published Online: 7 NOV 2008
DOI: 10.1002/9780470697047.ch12
Copyright © 2008 John Wiley & Sons, Ltd
Book Title

Anticancer Therapeutics
Additional Information
How to Cite
Bradshaw, T. D. (2008) Target-Directed Drug Discovery, in Anticancer Therapeutics (ed S. Missailidis), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470697047.ch12
Editor Information
Department of Chemistry and Analytical Sciences, The Open University, Milton Keynes, UK
Publication History
- Published Online: 7 NOV 2008
- Published Print: 21 NOV 2008
ISBN Information
Print ISBN: 9780470723036
Online ISBN: 9780470697047
- Summary
- Chapter
Keywords:
- target-directed drug discovery;
- ‘caretaker’ genes and mutations;
- non-small cell lung cancer (NSCLC) targeted therapy;
- EGFR inhibitors - Iressa and Tarceva;
- Gefinitib - EGFR inhibitor;
- chronic myeloid leukaemia pathogenesis;
- VEGFR signal transduction activation;
- targeting cell cycling;
- chemistry-driven drug discovery
Summary
This chapter contains sections titled:
Introduction
Tyrosine Kinases – Role and Significance in Cancer
Targeted Therapy for the Treatment of Non-small Cell Lung Cancer (NSCLC)
Targeted Therapy for the Treatment of Chronic Myeloid Leukaemia
Targeted Therapy for the Treatment of Breast Cancer
Angiogenesis
Targeting Cell Cycling
Targeting Apoptosis
Targeting mTOR
The Future of Molecularly Targeted Therapy
References
